List of Xcopri drug patents

Xcopri is owned by Sk Life.

Xcopri contains Cenobamate.

Xcopri has a total of 1 drug patent out of which 0 drug patents have expired.

Xcopri was authorised for market use on 10 March, 2020.

Xcopri is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Xcopri from March, 2024.

The generics of Xcopri are possible to be released after 30 October, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598279 SK LIFE Neurotherapeutic azole compounds
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 10 March, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

XCOPRI family patents

2

Korea, Republic of

2

United States

1

Brazil

1

Australia

1

Poland

1

Malaysia

1

Netherlands

1

Spain

1

Mexico

1

Japan

1

Argentina

1

South Africa

1

Portugal

1

Russia

1

China

1

Canada

1

Taiwan, Province of China

1

Denmark

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in